Genomix: Personalize Every Prescription

Empowering doctors with holistic, genomic patient insights for prescribing

Role

Co-Founder (sole designer)

Industry

Biotechnology & Healthtech

Duration

1 mo

Overview

Adverse drug reactions (ADRs) are unintended, harmful responses to medications. They're often caused by incorrect dosages, drug interactions, or genetic differences in how patients metabolize medications. ADRs account for 7.6% of annual hospital days, cost the U.S. healthcare industry $30 billion annually, and lead to 1 in 5 inpatient deaths.

Despite advancements in medicine, current prescribing practices rely on a generic, one-size-fits-all approach, putting patients at risk.

The Problem

The pain point is threefold.

Lack of Personalization: Current prescribing practices rely on a one-size-fits-all approach, ignoring genetic variability in patients.
Fragmented Electronic Health Records (EHRs): Inconsistent and incomplete data in fragmented EHRs disrupt seamless and personalized care. Nearly 20% of an organization’s patient records are duplicates, leading to repeated medical care, denied claims, and billions in annual costs to the healthcare industry.
High Risk of ADRs: Genetic differences in enzymes like CYP2D6 and CYP2C19 lead to severe side effects or ineffective treatment, making genotyping critical for safer prescribing. For instance, individuals with certain CYP2D6 polymorphisms metabolize drugs at a notably slower rate, leading to an accumulation of unmetabolized substances and a greater potential for adverse events (Oxford Academic).

These issues collectively compromise patient safety, highlight gaps in current practices, and increase the risks of medication management.

Overview

Despite advancements in medicine, current prescribing practices rely on a generic, one-size-fits-all approach, putting patients at risk.

The Problem

The pain point is threefold.

Lack of Personalization: Current prescribing practices rely on a one-size-fits-all approach, ignoring genetic variability in patients.
Fragmented Electronic Health Records (EHRs): Inconsistent and incomplete data in fragmented EHRs disrupt seamless and personalized care. Nearly 20% of an organization’s patient records are duplicates, leading to repeated medical care, denied claims, and billions in annual costs to the healthcare industry.
High Risk of ADRs: Genetic differences in enzymes like CYP2D6 and CYP2C19 lead to severe side effects or ineffective treatment, making genotyping critical for safer prescribing. For instance, individuals with certain CYP2D6 polymorphisms metabolize drugs at a notably slower rate, leading to an accumulation of unmetabolized substances and a greater potential for adverse events (Oxford Academic).

These issues collectively compromise patient safety, highlight gaps in current practices, and increase the risks of medication management.

The Solution

Genomix empowers cardiac doctors with holistic, genomic patient insights for prescribing medications (beta blockers) pre-surgery and post-surgery.

Integrated Dashboard: Genomix seamlessly integrates with existing EHR systems to provide a user-friendly dashboard for analyzing patient data, identifying drug interactions, and providing actionable insights.
Genomic Insights: AI-driven analytics flag risks, identify interactions, and recommend medications or dosages tailored to the patient’s genetics.

Genomix can analyze beta blockers, such as Metoprolol or Propranolol, predict metabolism issues, and recommend safer alternatives to prevent complications.

Competitor Analysis

Genomix effectively addresses critical gaps in healthcare technology by integrating genomic insights into e-prescription services, a feature absent in platforms like RXNT and iPrescribe. While RXNT excels in comprehensive EHR integration and offers robust record-keeping and standardized e-prescription tools, it lacks the ability to personalize treatments based on patient genetics - a key factor in precision medicine.

Genomix surpasses these foundational features by integrating advanced genomic tools, empowering doctors to predict drug responses, flag interactions, and personalize prescriptions for better outcomes. This personalized approach not only enhances patient safety but also empowers healthcare providers to deliver more effective, proactive care.

Business Model

Genomix has a flexible, tiered subscription model designed to meet the needs of healthcare providers of all stages. The base annual subscription is priced at $400, offering coverage for up to 500 patients. For larger practices and hospital networks, the pricing adjusts with a scalable structure, ensuring accessibility while maintaining affordability.

To optimize expenses, Genomix will partner with third-party sequencing services like Nucleus, capable of processing 25,000 patient samples per batch. This collaboration not only reduces sequencing costs but also ensures high-quality, reliable genomic data. By leveraging such partnerships, Genomix delivers advanced precision medicine solutions without imposing financial burdens on healthcare providers.

Timeline

Phase 1 - Beta Blockers: Our initial phase will target cardiovascular treatments, leveraging genetic insights to optimize beta blocker dosages for individual patients. By addressing common metabolic variations, this phase reduces the risk of side effects and ensures more effective treatment outcomes.

Phase 2 - Genotype Integration: This phase involves adding genetic markers to predict interactions and provide real-time alerts. This phase enhances the platform's ability to identify high-risk interactions before they occur. By integrating genetic markers with patient data, doctors can make more precise prescribing decisions, minimizing adverse reactions.

Phase 3 - Surgery Prep Tools: Optimize drug protocols using genotype data and real-time metrics. This phase focuses on preoperative and postoperative care, combining genomic data with live patient metrics to adjust medications dynamically, aiming to reduce complications during surgery.

Phase 4 - Precision Care Expansion: Expand to multi-surgery scenarios and additional drug classes. Expanding beyond cardiovascular care, this phase incorporates other drug categories and complex surgery scenarios. By integrating AI-driven updates, it ensures that personalized prescribing becomes a standard across diverse medical specialties.